Mesoblast has received FDA approval to implement a new potency assay for its approved cell therapy product Ryoncil, a regulatory milestone that addresses the quality control requirements as the company scales manufacturing and potentially brings the therapy to new production facilities.
The T-cell Proliferation Inhibition BioAssay (TIBA) will supplement existing potency assays to ensure Ryoncil maintains consistent potency across commercial batches. Mesoblast will use TIBA alongside its existing IL-2Rα inhibition and Cell Adhesion and Proliferation (CAP) assays to release each batch of the therapy, creating a matrix of quality measures that validate the product’s consistency and clinical effectiveness. This layered approach to quality control reflects FDA expectations for an industrially manufactured cellular medicine scaling production.
The approval carries practical significance for Mesoblast’s commercial expansion. Ryoncil is the first FDA-approved mesenchymal stromal cell (MSC) therapy and the only MSC product approved for steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged 2 months and older. The company has indicated it may manufacture this therapy in new facilities, and TIBA provides the assay framework FDA requires to ensure product quality does not drift as manufacturing moves to new sites or processes evolve. The regulatory alignment demonstrated here matters because manufacturing changes for cellular therapies typically require FDA sign-off, and pre-approval of the new assay removes a potential bottleneck.
For investors, this milestone sits between clinical validation and commercial scaling. Ryoncil’s clinical efficacy is established, but cellular therapies depend entirely on manufacturing consistency to deliver that efficacy at commercial scale. Mesoblast and the FDA have been working closely on this advancement since the therapy’s commercial approval, suggesting an orderly regulatory relationship and the company’s credibility with the regulator. The assay approval indicates FDA confidence that Mesoblast can scale and maintain product quality.
Beyond Ryoncil’s current indication, Mesoblast is developing the therapy for additional inflammatory diseases including steroid-refractory acute graft versus host disease in adults and biologic-resistant inflammatory bowel disease. A separate program with rexlemestrocel-L targets heart failure and chronic low back pain. The company holds patent protection extending through at least 2044 across major markets and maintains facilities in Australia, the United States, and Singapore. Manufacturing scale and quality confidence at this stage could prove valuable if any of these pipeline programs advance to commercialization.
Investors should monitor whether Mesoblast announces expansion into new manufacturing facilities and how quickly the company brings Ryoncil to additional markets through its established commercial partnerships in Japan, Europe, and China. Any updates on pipeline programs, particularly the inflammatory bowel disease indication, will signal the company’s confidence in its technology platform’s broader application. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Mesoblast Limited (ASX: MSB)
Mesoblast Limited is a biotechnology company headquartered in Melbourne, Australia, specializing in the development of allogeneic cellular medicines derived from adult stem cells. The company focuses on treating severe and life-threatening inflammatory conditions, with a pipeline spanning cardiovascular diseases, spine orthopedic disorders, and immune-mediated conditions. It is a world leader in the development of off-the-shelf cellular medicine therapies for these therapeutic areas.
If you would like to discuss this announcement, request a callback or call us on 1300 889 603.
